ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
ScripNews that oncologist Vinay Prasad will be the new head of the US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) division sent biopharma shares tumbling on 6 May, as
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripPTC Therapeutics presented an update of its Phase II study of PTC518 (votoplam) in Huntington’s disease with data from more patients and over a longer duration of therapy on 5 May, but investors and a